‘Right-Sizing’ Surveillance Intervals for CRC: Considerations for Now and the Future

AUGUST 25, 2025

Access to Oncology Drugs Stymied by Prior Authorization, but Specialty Pharmacists Can Help

AUGUST 22, 2025

Inflammatory Diet Associated With Worse Survival in Patients With Stage III Colon Cancer

AUGUST 20, 2025

Email This Article

POSTED: JANUARY 16, 2017

mTOR Inhibitor AEs May Be Surrogate Markers of Treatment Efficacy

Patients with metastatic renal cell carcinoma (mRCC) who experience more—and more severe—toxicities related to mechanistic target of rapamycin inhibitors (mTORi) are more likely to respond to treatment.
A link to this article will be included in this email.

Recipient's Email Address:

Enter email addresses separated by commas if sending to more than one person. (200 characters max)

Your Name:

Your Email Address:

Send me a copy

Personal Message: (Optional)

These email addresses will only be used to send out this message.

Please wait..

Solid Tumors

JANUARY 16, 2017

mTOR Inhibitor AEs May Be Surrogate Markers of Treatment Efficacy

To read the full story, Log in or Sign up for a Free Account

Check out our new Clinical tab!

We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!

The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com

First Name

Last Name

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select